N/A N=78 Evaluation of Marketed Contact Lens Disinfectant Systems on Eyelid Tissues
Contact Lens Care
Primary: Maximum Papillae — 2.0; 2.0; 2.0; 2.0 Units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=14 Marinol in Trichotillomania or Obsessive Compulsive Disorder
Trichotillomania · Obsessive Compulsive Disorder
Primary: Massachusetts General Hospital Hairpulling Scale (MGH-HPS) Total Score — 8.71 units on a scale
N/A N=39 Fruit and Vegetable Juice Concentrate Effects on RBP4 and Antioxidant Capacity in Lean and Overweight 6-10 Year Old Boys
Obesity
Primary: Beta-carotene Levels Between Overweight and Lean Boys at Baseline — 0.22; 0.29 mM/L
Phase 2 N=55 Pentoxifylline in Patients With Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Primary: Histological Improvement of at Least 2 Points in NAFLD Activity Score (NAS) on Liver Biopsy After One Year. — -1.6; -0.1 NAS score units
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 3 N=855 Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 16.8; 1.7 percentage of subjects — p=<0.025
Phase 2 N=80 Parathyroid Hormone (PTH) for Osteoporosis in Postmenopausal Women
Postmenopausal Osteoporosis · Osteoporosis
Primary: Changes in Indices of Bone Turnover — 4418; 3696; 956; 822 months*(ng/ml - baseline ng/ml)
Phase 3 N=53 Biological Markers of Response to Treatment in Major Depressive Disorder
Major Depressive Disorder
Primary: Serum Brain-derived Neurotrophic Factor (BDNF) Levels — 6077.270; 4393.24 pg/mL
Phase 3 N=668 Comparative Study of Modified Release (MR) Tacrolimus/Mycophenolate Mofetil (MMF) in de Novo Kidney Transplant Recipients
Kidney Transplantation
Primary: Percentage of Participants With Efficacy Failure — 15.1; 14.0; 17.0 percentage of participants
Phase 2 N=160 Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
Cancer
Primary: Overall Survival — 8.4; 6.7 months — p=0.352
Phase 4 N=112 Lamotrigine add-on Therapy for Bipolar Disorder and Cocaine Dependency
Bipolar Disorder · Cocaine Dependence
Primary: Days of Cocaine Use — 1.8; 2.8 days
Phase 4 N=1,137 A Study of LUMIGAN® RC in the Clinical Setting
Glaucoma, Primary Open Angle · Ocular Hypertension
Primary: Percentage of Treatment-Naive Patients With Ocular Hyperemia — 32.2; 39.8; 21.3; 5.9 Percentage of Patients
Phase 4 N=23 Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
Inflammation · Pseudophakia
Primary: Early Treatment Diabetic Retinopathy Study (ETDRS) Visual Acuities — 51.3; 52 letters
Phase 3 N=860 Evaluation of the Efficacy and Safety of NAFT-600 in Subjects With Tinea Pedis
Tinea Pedis
Primary: Complete Cure of Interdigital Tinea Pedis — 26.0; 3.3 percentage of subjects — p=<0.025
Phase 2 N=48 Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
Essential Thrombocythemia · Polycythemia Vera · Primary Myelofibrosis
Primary: Overall Response Rate — 0.26 Proportion of participants